GlassScriptPhysician profile
Jaison Ninan
NPI 1689244675
$1,606.43
in general payments reported to CMS, 2019-2025
26 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $249 · 2022: $219 · 2023: $295 · 2024: $537 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $186.70 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Axonics, INC. | $179.91 | 2024 | Bulkamid, Axonics |
| Inspire Medical Systems, INC. | $160.63 | 2025 | Inspire |
| Endo USA, INC. | $147.11 | 2024 | Xiaflex |
| Novo Nordisk INC | $146.92 | 2021-2022 | |
| Boston Scientific Corporation | $145.73 | 2025 | Ams 700 |
| Axsome Therapeutics, INC. | $135.94 | 2023 | Sunosi |
| Urogen Pharma, INC. | $69.11 | 2024 | |
| Progenics Pharmaceuticals, INC. | $43.23 | 2024 | |
| Lilly USA, LLC | $41.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.08 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.60 | 2021-2024 | |
| Biohaven Pharmaceuticals, INC. | $33.91 | 2021 | |
| Horizon Therapeutics Plc | $31.05 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.04 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.24 | 2021 | |
| Janssen Biotech, INC. | $26.99 | 2024 | Erleada |
| Abbvie INC. | $19.26 | 2021 | |
| Sumitomo Pharma America, INC. | $18.32 | 2024 | Orgovyx |
| Verity Pharmaceuticals INC. | $17.20 | 2024 | Trelstar |
| Alnylam Pharmaceuticals INC. | $14.91 | 2021 | |
| Astellas Pharma US INC | $11.72 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.67 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.26 | 2021 | |
| Amarin Pharma, INC. | $11.22 | 2021 | |
| Genentech USA, INC. | $8.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaison Ninan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.